Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time

1. Record Sales: Sanofi's Dupixent sales reached €3,303 million in the second quarter, a 29.2% increase and the first time above the €3 billion mark.
2. Strong Performance: Sanofi reported a 10.2% sales growth at constant exchange rates (CER) and business EPS of €1.73.
3. Earnings Forecast Upgrade: Sanofi upgraded its 2024 business EPS guidance to be stable at CER, driven by strong demand for Dupixent and new product launches.
4. Pipeline Progress: Sanofi achieved three regulatory approvals, including Dupixent for COPD, and four regulatory submissions, with 12 phase 3 data readouts expected over 2024-2025.
5. Sustainability Recognition: Sanofi was ranked the world's 7th most sustainable company by TIME Magazine.